P193  Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis

Conclusion In this analysis, patients who did not respond to ADA but subsequently responded to IXE exhibited overall lower levels of inflammation, as measured by CRP and MRI of the spine or sacroiliac joints, compared with patients who responded on ADA and also after switching to IXE. Along with comparative findings in patients who continuously received IXE and responded at both wks16 and 52 or wk52 only, these data indicate that IXE is efficacious in patients with active AS irrespective of inflammation level, assessed by CRP and MRI. Alternatively, lower baseline inflammation may be a predictor of de layed response.Disclosure X. Baraliakos: Consultancies; X. Baraliakos has served as a consultant for AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp& Dohme, Novartis, Pfizer, Roche, and UCB Pharma. Grants/research support; X. Baraliakos has received research grants from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp& Dohme, Novartis, Pfizer, Roche, and UCB Pharma.R. Bolce: Shareholder/stock ownership; R. Bolce is a shareholder and employee of Eli Lilly and Company.D. Sandoval Calderon: Shareholder/stock ownership; D. Sandoval Calderon is a shareholder and employee of Eli Lilly and Company.S. Liu Leage: Shareholder/stock ownership; S.L. League is a shareholder and employee of Eli Lilly and Company.V. Geneus: Shareholder/stock ownership; V. Geneus is a shareholder and employee of Eli Lilly and Company.D. Adams: Shareholder/stock ownership; D. A...
Source: Rheumatology - Category: Rheumatology Source Type: research